The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.
 
Enrique Grande
Honoraria - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Eisai; Eusa Pharma; Genzyme; IPSEN; Janssen-Cilag; Lexicon; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Roche
Research Funding - AstraZeneca (Inst); Ipsen (Inst); Molecular Templates (Inst); Pfizer (Inst); Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Roche/Genentech
 
Teresa Alonso Gordoa
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer; Roche; Sanofi
Research Funding - Ipsen; Pfizer; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Pfizer; Sanofi
 
Oscar Reig Torras
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Pfizer
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Emilio Esteban
Travel, Accommodations, Expenses - Pfizer/EMD Serono; Pfizer/EMD Serono
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche
 
Xavier Garcia del Muro
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Lilly; Pfizer; PharmaMar; Roche
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Pfizer; PharmaMar
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
María José Mendez Vidal
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Roche
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Roche
 
Jesús García-Donas
Consulting or Advisory Role - Bristol-Myers Squibb; Clovis Oncology
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Janssen-Cilag; PharmaMar; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; GamaMabs Pharma; InvitroCue; Merck; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Jose Angel Arranz
Honoraria - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Janssen-Cilag; MSD Oncology; Roche Pharma AG
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Janssen-Cilag; Merck; MSD Oncology; Pfizer
Research Funding - Bristol-Myers Squibb; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Pfizer
 
Cristina Suarez Rodriguez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Sanofi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Ipsen; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Millennium (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche